


What is claimed:

1. At least one chemical entity chosen from compounds of Formula I

5

**Formula I**

and pharmaceutically acceptable salts and prodrugs thereof wherein:

R₁ is chosen from optionally substituted aryl and optionally substituted heteroaryl;

- 10 R₂ is chosen from cyano, optionally substituted heteroaryl and optionally substituted heterocycloalkyl;

R₃ is chosen from hydrogen and optionally substituted lower alkyl and

R₄ is chosen from hydrogen, halo, and optionally substituted lower alkyl.

- 15 2. At least one chemical entity of claim 1 wherein R₁ is phenyl optionally substituted with one, two, or three groups chosen from halo, optionally substituted lower alkyl, optionally substituted lower alkoxy, and hydroxy.

- 20 3. At least one chemical entity of claim 2 wherein R₁ is phenyl optionally substituted with one, two, or three groups chosen from halo, lower alkyl, trifluoromethyl, trifluoromethoxy, lower alkoxy, and hydroxy.

- 25 4. At least one chemical entity of claim 3 wherein R₁ is phenyl optionally substituted with one, two, or three groups chosen from halo, lower alkyl, trifluoromethoxy, and trifluoromethyl.

5. At least one chemical entity of claim 4 wherein R₁ is chosen from 3-chloro-4-trifluoromethoxyphenyl, 3-chloro-4-methylphenyl, 3-fluoro-4-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-4-isopropoxyphenyl, 3,4-difluorophenyl, 2-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chlorophenyl, 4-chlorophenyl, and 3,5-dichlorophenyl.

5

6. At least one chemical entity of claim 1 wherein R₁ is pyridin-3-yl optionally substituted with one, two, or three groups chosen from halo, lower alkyl, lower alkoxy, optionally substituted amino, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and hydroxy.

10

7. At least one chemical entity of claim 6 wherein R₁ is pyridin-3-yl optionally substituted with one, two, or three groups chosen from halo, optionally substituted lower alkyl, optionally substituted lower alkoxy, and hydroxy.

15

8. At least one chemical entity of claim 7 wherein R₁ is pyridin-3-yl optionally substituted with one, two, or three groups chosen from halo, lower alkyl, trifluoromethyl, lower alkoxy, and hydroxy.

20

9. At least one chemical entity of claim 8 wherein R₁ is pyridin-3-yl optionally substituted with one, two, or three groups chosen from halo, lower alkyl, and trifluoromethyl.

25

10. At least one chemical entity of any one of claims 1 to 9 wherein R₂ is chosen from thiazol-2-yl, 1H-pyrazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,2,4]oxadiazol-3-yl, 4H-[1,2,4]oxadiazol-5-one-3-yl, 4H-[1,2,4]oxadiazole-5-thione-3-yl, [1,2,4]triazol-1-yl, 1H-benzoimidazol-2-yl, 1H-tetrazol-5-yl, 2H-tetrazol-5-yl, tetrazol-1-yl, 2,4-dihydro-[1,2,4]triazol-3-one-5-yl, 4H-[1,2,4]triazol-3-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, oxazol-2-yl, pyridin-2-yl, benzooxazol-2-yl, imidazol-1-yl, piperazin-2-one-4-yl, pyrazol-1-yl, 1,6-dihydropyrimidin-5-yl, 2,3-dihydro-1H-pyrazol-4-yl, 2,3-dihydro-1H-imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, 2,5-dihydro-1H-pyrazol-1-yl, 1H-imidazol-1-yl, each of which is optionally substituted.

30

11. At least one chemical entity of claim 10 wherein R₂ is chosen from thiazol-2-yl, 1H-pyrazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,2,4]oxadiazol-3-yl, 4H-[1,2,4]oxadiazol-5-one-3-yl, 4H-[1,2,4]oxadiazole-5-thione-3-yl, [1,2,4]triazol-1-yl, 1H-benzoimidazol-2-yl, 1H-tetrazol-5-yl, 2H-tetrazol-5-yl, tetrazol-1-yl, 2,4-dihydro-[1,2,4]triazol-3-one-5-yl, 4H-[1,2,4]triazol-3-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, oxazol-2-yl, pyridin-2-yl, benzooxazol-2-yl, imidazol-1-yl, piperazin-2-one-4-yl, pyrazol-1-yl, 1,6-dihydropyrimidin-5-yl, 2,3-dihydro-1H-pyrazol-4-yl, 2,3-dihydro-1H-imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, 2,5-dihydro-1H-pyrazol-1-yl, and 1H-imidazol-1-yl, each of which is optionally substituted with one or two groups chosen from aminocarbonyl, optionally substituted amino, oxo, lower alkyl, trifluoromethyl, halo, and heterocycloalkyl.

12. At least one chemical entity of claim 11 wherein R₂ is chosen from thiazol-2-yl, 1H-pyrazol-3-yl, 3-methyl-[1,2,4]oxadiazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,2,4]triazol-1-yl, 1H-benzoimidazol-2-yl, 1H-tetrazol-5-yl, 1-methyl-1H-tetrazol-5-yl, 2,4-dihydro-[1,2,4]triazol-3-one-5-yl, 2-methyl-2H-tetrazol-5-yl, 3-trifluoromethyl-pyrazol-1-yl, 4H-[1,2,4]oxadiazol-5-one-3-yl, 4H-[1,2,4]oxadiazole-5-thione-3-yl, 4H-[1,2,4]triazol-3-yl, 4-methyl-1H-imidazol-2-yl, 4-methyl-oxazol-2-yl, 5-fluoro-pyridin-2-yl, 5-methyl-[1,2,4]oxadiazol-3-yl, tetrazol-1-yl, benzooxazol-2-yl, imidazol-1-yl, piperazin-2-one-4-yl, pyrazol-1-yl, 2-oxo-2,3-dihydro-1H-imidazol-4-yl, 6-oxo-1,6-dihydropyrimidin-5-yl, 1-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl, 2-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl, 1,2-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl, 2-amino-6-oxo-1,6-dihydropyrimidin-5-yl, 2-oxo-2,3-dihydro-1H-imidazol-1-yl, 3-methyl-2-oxo-2,3-dihydro-1H-imidazol-1-yl, 5-(methylcarbamoyl)pyridin-2-yl, 5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl, 5-methyl-4H-1,2,4-triazol-3-yl, 4,5-dihydro-1H-imidazol-2-yl, 3-methyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl, 1H-imidazol-2-yl, and 4-(trifluoromethyl)-1H-imidazol-1-yl.

13. At least one chemical entity of any one of claims 1 to 12 wherein R₄ is hydrogen.

14. At least one chemical entity of any one of claims 1 to 12 wherein R₄ is methyl.

15. At least one chemical entity of any one of claims 1 to 12 wherein R₄ is fluoro.

16. At least one chemical entity of any one of claims 1 to 15 wherein R₃ is hydrogen.
17. At least one chemical entity of claim 1 wherein the compound of Formula I is chosen from
- 5 4-(3-Chloro-phenyl)-6-(1H-tetrazol-5-yl)-pyrimidine;
4-(3-Chloro-phenyl)-6-(1-methyl-1H-tetrazol-5-yl)-pyrimidine;
4-(3-Chloro-phenyl)-6-(2-methyl-2H-tetrazol-5-yl)-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-(1H-tetrazol-5-yl)-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-(1-methyl-1H-tetrazol-5-yl)-pyrimidine;
10 4-(3,4-Dichloro-phenyl)-6-(2-methyl-2H-tetrazol-5-yl)-pyrimidine;
4-(3,4-Difluoro-phenyl)-6-(1H-tetrazol-5-yl)-pyrimidine;
4-(3-Chloro-4-fluoro-phenyl)-6-(1H-tetrazol-5-yl)-pyrimidine;
2-[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-1H-benzoimidazole;
2-[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-5,6-difluoro-1H-benzoimidazole;
15 2-[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-5-fluoro-1H-benzoimidazole;
2-[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-1-methyl-1H-benzoimidazole;
6-Chloro-2-[6-(3-chloro-phenyl)-pyrimidin-4-yl]-1H-benzoimidazole;
2-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-1H-benzoimidazole;
2-[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-benzooxazole;
20 4-(3-Chloro-phenyl)-6-(4-methyl-oxazol-2-yl)-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-(4-methyl-oxazol-2-yl)-pyrimidine;
4-(3,4-Dichloro-phenyl)-2-methyl-6-(4-methyl-oxazol-2-yl)-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-(4-methyl-1H-imidazol-2-yl)-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-[1,2,4]oxadiazol-3-yl-pyrimidine;
25 4-(3,4-Dichloro-phenyl)-6-(5-methyl-[1,2,4]oxadiazol-3-yl)-pyrimidine;
3-[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-4H-[1,2,4]oxadiazol-5-one;
3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-4H-[1,2,4]oxadiazol-5-one;
3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-4-methyl-4H-[1,2,4]oxadiazol-5-one;
3-[6-(5-Chloro-pyridin-3-yl)-pyrimidin-4-yl]-4H-[1,2,4]oxadiazol-5-one;
30 3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-4H-[1,2,4]oxadiazole-5-thione;
4-(3-Chloro-phenyl)-6-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrimidine;
4-(3-Chloro-phenyl)-6-(4H-[1,2,4]triazol-3-yl)-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-(4H-[1,2,4]triazol-3-yl)-pyrimidine;

- 5-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-2,4-dihydro-[1,2,4]triazol-3-one;
4-{3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-[1,2,4]oxadiazol-5-yl}-morpholine;
{3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-[1,2,4]oxadiazol-5-yl}-dimethyl-amine;
(2-{3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-[1,2,4]oxadiazol-5-yl}-ethyl)-dimethyl-
5 amine;
4-(3,4-Dichloro-phenyl)-6-(5-fluoro-pyridin-2-yl)-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-(4-trifluoromethyl-imidazol-1-yl)-pyrimidine;
1-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-1,3-dihydro-imidazol-2-one;
1-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-3-methyl-1,3-dihydro-imidazol-2-one;
10 6-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-N-methyl-nicotinamide;
2-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-5-methyl-1,2-dihydro-pyrazol-3-one;
4-(3,4-Dichloro-phenyl)-6-(4,5-dihydro-1H-imidazol-2-yl)-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-(1H-imidazol-2-yl)-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-(5-methyl-4H-[1,2,4]triazol-3-yl)-pyrimidine;
15 4-(3,4-Dichloro-phenyl)-6-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-pyrimidine;
6-(3,4-Dichloro-phenyl)-3'H-[4,5']bipyrimidinyl-4'-one;
4-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-2-methyl-1,2-dihydro-pyrazol-3-one;
2'-Amino-6-(3,4-dichloro-phenyl)-3'H-[4,5']bipyrimidinyl-4'-one;
4-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-1,2-dimethyl-1,2-dihydro-pyrazol-3-one;
20 4-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-1,3-dihydro-imidazol-2-one;
4-(3,4-Dichloro-phenyl)-6-[1,2,4]triazol-1-yl-pyrimidine;
4-(3-Chloro-phenyl)-6-[1,2,4]triazol-1-yl-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-imidazol-1-yl-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-pyrazol-1-yl-pyrimidine;
25 4-(3-Chloro-phenyl)-6-imidazol-1-yl-pyrimidine;
4-(3-Chloro-phenyl)-6-pyrazol-1-yl-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-(3-trifluoromethyl-pyrazol-1-yl)-pyrimidine;
4-(3-Chloro-phenyl)-6-tetrazol-1-yl-pyrimidine;
4-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-piperazin-2-one;
30 4-[6-(3,5-Dichloro-phenyl)-pyrimidin-4-yl]-piperazin-2-one,
3-[6-(3,4-Difluoro-phenyl)-pyrimidin-4-yl]-4H-[1,2,4]oxadiazol-5-one;
3-[6-(3-Chloro-4-trifluoromethoxy-phenyl)-pyrimidin-4-yl]-4H-[1,2,4]oxadiazol-5-one;
3-[6-(3-Chloro-4-methyl-phenyl)-pyrimidin-4-yl]-4H-[1,2,4]oxadiazol-5-one;

- 3-[6-(3-Fluoro-4-methyl-phenyl)-pyrimidin-4-yl]-4H-[1,2,4]oxadiazol-5-one;
4-(3-Fluoro-4-methyl-phenyl)-6-(1H-tetrazol-5-yl)-pyrimidine;
3-[6-(3-Chloro-4-fluoro-phenyl)-pyrimidin-4-yl]-4H-[1,2,4]oxadiazol-5-one;
4-(3-Chloro-4-isopropoxy-phenyl)-6-(1H-tetrazol-5-yl)-pyrimidine;
5 3-[6-(3-Chloro-4-isopropoxy-phenyl)-pyrimidin-4-yl]-4H-[1,2,4]oxadiazol-5-one;
4-(3-Chloro-4-trifluoromethoxy-phenyl)-6-(1H-tetrazol-5-yl)-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-oxazol-2-yl-pyrimidine;
4-(3,4-Dichloro-phenyl)-6-thiazol-2-yl-pyrimidine; and
4-(3,4-Dichloro-phenyl)-6-(1H-pyrazol-3-yl)-pyrimidine, and
10 pharmaceutically acceptable salts and prodrugs thereof.

18. At least one chemical entity of claim 1 wherein the pharmaceutically acceptable salt of a compound of Formula I is chosen from
4-(3,4-difluorophenyl)-6-(1H-tetrazol-5-yl)-pyrimidine, sodium salt;
15 4-(3-Chloro-4-fluoro-phenyl)-6-(1H-tetrazol-5-yl)-pyrimidine, sodium salt;
4-(3,4-Dichloro-phenyl)-6-(1H-tetrazol-5-yl)-pyrimidine sodium salt; and
6'-(3-Chloro-phenyl)-[1,4']bipyrimidinyl-2,4-dione, potassium salt.

19. A pharmaceutical composition comprising at least one chemical entity of any one
20 of claims 1 to 18 and at least one pharmaceutically acceptable excipient.

20. A method of treating a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity in a subject in need of such a treatment which method comprises administering to the subject a therapeutically effective amount of at least one chemical
25 entity of any one of claims 1 to 18.

21. The method of claim 20 wherein at least one chemical entity binds Kynurenine 3-mono-oxygenase.

- 30 22. The method of claim 20 wherein said condition or disorder involves a neurodegenerative pathology.

23. The method of claim 22 wherein the neurodegenerative pathology is selected from Huntington's disease, Alzheimer's disease, Parkinson's disease, olivoponto cerebellar atrophy, non-Alzheimer's dementia, multi-infarctual dementia, cerebral amyotrophic lateral sclerosis, cerebral ischemia, cerebral hypoxia, spinal or head trauma and epilepsy.

5


24. A packaged pharmaceutical composition comprising at least one pharmaceutical composition according claim 19 and instructions for using the composition to treat a subject suffering from a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity.

10

25. The packaged pharmaceutical composition according to claim 24, wherein the condition or disorder is Huntington's disease.

What is claimed is:

1. At least one chemical entity chosen from compounds of Formula I



and pharmaceutically acceptable salts thereof wherein:

R₁ is phenyl substituted with one, two, or three groups chosen from halo, optionally substituted lower alkyl, optionally substituted lower alkoxy, and hydroxyl;

R₂ is chosen from [1,2,4]oxadiazol-5-yl, [1,2,4]oxadiazol-3-yl, 4*H*-[1,2,4]oxadiazol-5-one-3-yl, 4*H*-[1,2,4]oxadiazole-5-thione-3-yl, [1,2,4]triazol-1-yl, 1*H*-tetrazol-5-yl, 2*H*-tetrazol-5-yl, tetrazol-1-yl, 2,4-dihydro-[1,2,4]triazol-3-one-5-yl, 4*H*-[1,2,4]triazol-3-yl, each of which is optionally substituted;

R₃ is chosen from hydrogen and optionally substituted lower alkyl and

R₄ is chosen from hydrogen, halo, and optionally substituted lower alkyl.

2. At least one chemical entity of claim 1 wherein R₁ is phenyl substituted with one, two, or three groups chosen from halo, lower alkyl, trifluoromethyl, trifluoromethoxy, lower alkoxy, and hydroxy.
3. At least one chemical entity of claim 2 wherein R₁ is phenyl substituted with one, two, or three groups chosen from halo, lower alkyl, trifluoromethoxy, and trifluoromethyl.
4. At least one chemical entity of claim 3 wherein R₁ is chosen from 3-chloro-4-trifluoromethoxyphenyl, 3-chloro-4-methylphenyl, 3-fluoro-4-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-4-isopropoxyphenyl, 3,4-difluorophenyl, 2-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chlorophenyl, 4-chlorophenyl, and 3,5-dichlorophenyl.

5. At least one chemical entity of claim 1 wherein R₂ is chosen from [1,2,4]oxadiazol-5-yl, [1,2,4]oxadiazol-3-yl, 4*H*-[1,2,4]oxadiazol-5-one-3-yl, 4*H*-[1,2,4]oxadiazole-5-thione-3-yl, [1,2,4]triazol-1-yl, 1*H*-tetrazol-5-yl, 2*H*-tetrazol-5-yl, tetrazol-1-yl, 2,4-dihydro-[1,2,4]triazol-3-one-5-yl, and 4*H*-[1,2,4]triazol-3-yl, each of which is optionally substituted with one or two groups chosen from aminocarbonyl, optionally substituted amino, oxo, lower alkyl, trifluoromethyl, halo, and heterocycloalkyl.
6. At least one chemical entity of claim 5 wherein R₂ is chosen from 3-methyl-[1,2,4]oxadiazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,2,4]triazol-1-yl, 1*H*-tetrazol-5-yl, 1-methyl-1*H*-tetrazol-5-yl, 2,4-dihydro-[1,2,4]triazol-3-one-5-yl, 2-methyl-2*H*-tetrazol-5-yl, 4*H*-[1,2,4]oxadiazol-5-one-3-yl, 4*H*-[1,2,4]oxadiazole-5-thione-3-yl, 4*H*-[1,2,4]triazol-3-yl, 5-methyl-[1,2,4]oxadiazol-3-yl, tetrazol-1-yl, 5-(trifluoromethyl)-[1,2,4]oxadiazol-3-yl, and 5-methyl-4*H*-[1,2,4]triazol-3-yl.
7. At least one chemical entity of claim 1 wherein R₄ is hydrogen.
8. At least one chemical entity of claim 1 wherein R₄ is methyl.
9. At least one chemical entity of claim 1 wherein R₄ is fluoro.
10. At least one chemical entity of claim 1 wherein R₃ is hydrogen.
11. At least one chemical entity of claim 1 wherein the compound of Formula I is chosen from 4-(3-Chloro-phenyl)-6-(1*H*-tetrazol-5-yl)-pyrimidine; 4-(3-Chloro-phenyl)-6-(1-methyl-1*H*-tetrazol-5-yl)-pyrimidine; 4-(3-Chloro-phenyl)-6-(2-methyl-2*H*-tetrazol-5-yl)-pyrimidine; 4-(3,4-Dichloro-phenyl)-6-(1*H*-tetrazol-5-yl)-pyrimidine; 4-(3,4-Dichloro-phenyl)-6-(1-methyl-1*H*-tetrazol-5-yl)-pyrimidine; 4-(3,4-Dichloro-phenyl)-6-(2-methyl-

2H-tetrazol-5-yl)-pyrimidine; 4-(3,4-Difluoro-phenyl)-6-(1*H*-tetrazol-5-yl)-pyrimidine; 4-(3-Chloro-4-fluoro-phenyl)-6-(1*H*-tetrazol-5-yl)-pyrimidine; 4-(3,4-Dichloro-phenyl)-6-[1,2,4]oxadiazol-3-yl-pyrimidine; 4-(3,4-Dichloro-phenyl)-6-(5-methyl-[1,2,4]oxadiazol-3-yl)-pyrimidine; 3-[6-(3-Chloro-phenyl)-pyrimidin-4-yl]-4*H*-[1,2,4]oxadiazol-5-one; 3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-4*H*-[1,2,4]oxadiazol-5-one; 3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-4-methyl-4*H*-[1,2,4]oxadiazol-5-one; 3-[6-(5-Chloro-pyridin-3-yl)-pyrimidin-4-yl]-4*H*-[1,2,4]oxadiazol-5-one; 3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-4*H*-[1,2,4]oxadiazole-5-thione; 4-(3-Chloro-phenyl)-6-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrimidine; 4-(3-Chloro-phenyl)-6-(4*H*-[1,2,4]triazol-3-yl)-pyrimidine; 4-(3,4-Dichloro-phenyl)-6-(4*H*-[1,2,4]triazol-3-yl)-pyrimidine; 5-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-2,4-dihydro-[1,2,4]triazol-3-one; 4-{3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-[1,2,4]oxadiazol-5-yl}-morpholine; {3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-[1,2,4]oxadiazol-5-yl}-dimethyl-amine; (2-{3-[6-(3,4-Dichloro-phenyl)-pyrimidin-4-yl]-[1,2,4]oxadiazol-5-yl}-ethyl)-dimethyl-amine; 4-(3,4-Dichloro-phenyl)-6-(5-methyl-4*H*-[1,2,4]triazol-3-yl)-pyrimidine; 4-(3,4-Dichloro-phenyl)-6-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-pyrimidine; 4-(3,4-Dichloro-phenyl)-6-[1,2,4]triazol-1-yl-pyrimidine; 4-(3-Chloro-phenyl)-6-[1,2,4]triazol-1-yl-pyrimidine; 4-(3-Chloro-phenyl)-6-tetrazol-1-yl-pyrimidine; 3-[6-(3,4-Difluoro-phenyl)-pyrimidin-4-yl]-4*H*-[1,2,4]oxadiazol-5-one; 3-[6-(3-Chloro-4-trifluoromethoxy-phenyl)-pyrimidin-4-yl]-4*H*-[1,2,4]oxadiazol-5-one; 3-[6-(3-Chloro-4-methyl-phenyl)-pyrimidin-4-yl]-4*H*-[1,2,4]oxadiazol-5-one; 3-[6-(3-Fluoro-4-methyl-phenyl)-pyrimidin-4-yl]-4*H*-[1,2,4]oxadiazol-5-one; 4-(3-Fluoro-4-methyl-phenyl)-6-(1*H*-tetrazol-5-yl)-pyrimidine; 3-[6-(3-Chloro-4-fluoro-phenyl)-pyrimidin-4-yl]-4*H*-[1,2,4]oxadiazol-5-one; 4-(3-Chloro-4-isopropoxy-phenyl)-6-(1*H*-tetrazol-5-yl)-pyrimidine; 3-[6-(3-Chloro-4-isopropoxy-phenyl)-pyrimidin-4-yl]-4*H*-[1,2,4]oxadiazol-5-one; and 4-(3-Chloro-4-trifluoromethoxy-phenyl)-6-(1*H*-tetrazol-5-yl)-pyrimidine, and pharmaceutically acceptable salts thereof.

12. At least one chemical entity of claim 1 wherein the pharmaceutically acceptable salt of a

compound of Formula I is chosen from 4-(3,4-difluorophenyl)-6-(1*H*-tetrazol-5-yl)-pyrimidine, sodium salt; 4-(3-Chloro-4-fluoro-phenyl)-6-(1*H*-tetrazol-5-yl)-pyrimidine, sodium salt; and 4-(3,4-Dichloro-phenyl)-6-(1*H*-tetrazol-5-yl)-pyrimidine sodium salt.

13. A pharmaceutical composition comprising at least one chemical entity of claim 1 and at least one pharmaceutically acceptable excipient.